MX2007003032A - Analogos de loxapina y metodos de uso de los mismos. - Google Patents

Analogos de loxapina y metodos de uso de los mismos.

Info

Publication number
MX2007003032A
MX2007003032A MX2007003032A MX2007003032A MX2007003032A MX 2007003032 A MX2007003032 A MX 2007003032A MX 2007003032 A MX2007003032 A MX 2007003032A MX 2007003032 A MX2007003032 A MX 2007003032A MX 2007003032 A MX2007003032 A MX 2007003032A
Authority
MX
Mexico
Prior art keywords
methods
loxapine analogs
loxapine
analogs
relates
Prior art date
Application number
MX2007003032A
Other languages
English (en)
Inventor
Kazumi Shiosaki
Dale M Edgar
David G Hangauer
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of MX2007003032A publication Critical patent/MX2007003032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a compuestos y metodos novedosos para usuarios en la modulacion del sueno.
MX2007003032A 2004-09-21 2005-09-21 Analogos de loxapina y metodos de uso de los mismos. MX2007003032A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
PCT/US2005/034015 WO2006034414A2 (en) 2004-09-21 2005-09-21 Loxapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2007003032A true MX2007003032A (es) 2007-05-21

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003032A MX2007003032A (es) 2004-09-21 2005-09-21 Analogos de loxapina y metodos de uso de los mismos.

Country Status (19)

Country Link
US (3) US7592333B2 (es)
EP (1) EP1804804B1 (es)
JP (1) JP5049129B2 (es)
KR (1) KR101264444B1 (es)
AT (1) ATE542536T1 (es)
AU (1) AU2005286713B2 (es)
BR (1) BRPI0515518A (es)
CA (1) CA2580250C (es)
CY (1) CY1112590T1 (es)
DK (1) DK1804804T3 (es)
EA (1) EA012610B1 (es)
ES (1) ES2378452T3 (es)
MA (1) MA28985B1 (es)
MX (1) MX2007003032A (es)
NO (1) NO20071604L (es)
NZ (1) NZ553900A (es)
PL (1) PL1804804T3 (es)
PT (1) PT1804804E (es)
WO (1) WO2006034414A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CA2512043A1 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
US7563785B2 (en) * 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
KR101312993B1 (ko) * 2006-10-28 2013-11-25 엔비보 파마슈티칼즈, 인코퍼레이티드 히스톤 데아세틸라아제의 억제제
EP2137180B1 (en) * 2007-03-15 2012-03-07 Aryx Therapeutics, Inc. Dibenzo [b,f][1,4] oxazapine compounds
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
EP2355758A2 (en) 2008-11-07 2011-08-17 Insuline Medical Ltd. Device and method for drug delivery
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
ES2926494T3 (es) 2015-03-26 2022-10-26 Sen Jam Pharmaceutical Llc Combinación de naproxeno y fexofenadina para inhibir los síntomas asociados con veisalgia
AU2020370063A1 (en) 2019-10-21 2022-06-02 Alairion, Inc. 3-(4-(llH-dibenzo[b,e][l,4]azepin-6- yl)piperazin-l-yl)- and 3- (4-(dibenzo[b,f][l,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propano ic acid derivatives as HI and 5- HT2A-receptor modulators for the treatment of sleep disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (es) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
EP0804170B1 (en) 1993-07-09 2001-11-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
CA2281473C (en) 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
WO2003039255A1 (en) 2001-11-05 2003-05-15 Basf Aktiengesellschaft Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
WO2004056182A1 (en) * 2002-12-20 2004-07-08 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
CA2580250A1 (en) 2006-03-30
NO20071604L (no) 2007-06-20
CY1112590T1 (el) 2016-02-10
MA28985B1 (fr) 2007-11-01
US7592333B2 (en) 2009-09-22
US8101596B2 (en) 2012-01-24
AU2005286713B2 (en) 2010-10-28
NZ553900A (en) 2010-10-29
KR101264444B1 (ko) 2013-05-20
WO2006034414A2 (en) 2006-03-30
BRPI0515518A (pt) 2008-07-29
ES2378452T3 (es) 2012-04-12
PT1804804E (pt) 2012-03-30
EA200700702A1 (ru) 2007-10-26
EP1804804B1 (en) 2012-01-25
EA012610B1 (ru) 2009-10-30
JP5049129B2 (ja) 2012-10-17
PL1804804T3 (pl) 2012-08-31
EP1804804A2 (en) 2007-07-11
KR20070060126A (ko) 2007-06-12
AU2005286713A1 (en) 2006-03-30
DK1804804T3 (da) 2012-02-20
WO2006034414A3 (en) 2006-09-08
JP2008513510A (ja) 2008-05-01
EP1804804A4 (en) 2010-11-24
US20060063928A1 (en) 2006-03-23
CA2580250C (en) 2013-05-14
ATE542536T1 (de) 2012-02-15
US20060063755A1 (en) 2006-03-23
US20090186872A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2007003032A (es) Analogos de loxapina y metodos de uso de los mismos.
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
TW200716624A (en) Compounds for modulating TRPV3 function
TW200626068A (en) Active compounds for seed treatment
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
SG173374A1 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
EP1718308A4 (en) PROCESS FOR MODULATING NEUROTROPHINE-MEDIATED ACTIVITY
SG145694A1 (en) Novel compounds
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
IN2014CN03629A (es)
AU2003254177A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
MX2007001127A (es) Moduladores de pirrolo-piridina cinasa.
AU2003256923A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
TW200603823A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
IL176932A0 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
TW200505875A (en) Novel compounds
WO2005105110A3 (en) Doxepin analogs and methods of use thereof
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
PL1668001T3 (pl) Podstawione heteroarylobenzofuranowe kwasy
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
MY162185A (en) Alumina particles and methods of making the same
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration